vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Northfield Bancorp, Inc. (NFBK). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $41.3M, roughly 1.8× Northfield Bancorp, Inc.). Health Catalyst, Inc. runs the higher net margin — -121.9% vs -1545.5%, a 1423.6% gap on every dollar of revenue. On growth, Northfield Bancorp, Inc. posted the faster year-over-year revenue change (12.7% vs -6.2%). Northfield Bancorp, Inc. produced more free cash flow last quarter ($52.5M vs $9.6M). Over the past eight quarters, Northfield Bancorp, Inc.'s revenue compounded faster (15.0% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.

HCAT vs NFBK — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.8× larger
HCAT
$74.7M
$41.3M
NFBK
Growing faster (revenue YoY)
NFBK
NFBK
+18.9% gap
NFBK
12.7%
-6.2%
HCAT
Higher net margin
HCAT
HCAT
1423.6% more per $
HCAT
-121.9%
-1545.5%
NFBK
More free cash flow
NFBK
NFBK
$42.9M more FCF
NFBK
$52.5M
$9.6M
HCAT
Faster 2-yr revenue CAGR
NFBK
NFBK
Annualised
NFBK
15.0%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
NFBK
NFBK
Revenue
$74.7M
$41.3M
Net Profit
$-91.0M
$-27.4M
Gross Margin
Operating Margin
-115.3%
-1263.3%
Net Margin
-121.9%
-1545.5%
Revenue YoY
-6.2%
12.7%
Net Profit YoY
-340.3%
-343.6%
EPS (diluted)
$-1.29
$-0.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
NFBK
NFBK
Q4 25
$74.7M
$41.3M
Q3 25
$76.3M
$39.2M
Q2 25
$80.7M
$38.9M
Q1 25
$79.4M
$34.8M
Q4 24
$79.6M
$36.7M
Q3 24
$76.4M
$31.8M
Q2 24
$75.9M
$31.5M
Q1 24
$74.7M
$31.3M
Net Profit
HCAT
HCAT
NFBK
NFBK
Q4 25
$-91.0M
$-27.4M
Q3 25
$-22.2M
$10.8M
Q2 25
$-41.0M
$9.6M
Q1 25
$-23.7M
$7.9M
Q4 24
$-20.7M
$11.3M
Q3 24
$-14.7M
$6.5M
Q2 24
$-13.5M
$6.0M
Q1 24
$-20.6M
$6.2M
Gross Margin
HCAT
HCAT
NFBK
NFBK
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
NFBK
NFBK
Q4 25
-115.3%
-1263.3%
Q3 25
-22.9%
37.7%
Q2 25
-46.0%
35.6%
Q1 25
-25.4%
31.0%
Q4 24
-22.0%
38.0%
Q3 24
-17.9%
27.9%
Q2 24
-20.8%
29.1%
Q1 24
-30.5%
27.2%
Net Margin
HCAT
HCAT
NFBK
NFBK
Q4 25
-121.9%
-1545.5%
Q3 25
-29.1%
27.4%
Q2 25
-50.8%
24.6%
Q1 25
-29.9%
22.6%
Q4 24
-26.0%
30.7%
Q3 24
-19.3%
20.5%
Q2 24
-17.8%
18.9%
Q1 24
-27.6%
19.9%
EPS (diluted)
HCAT
HCAT
NFBK
NFBK
Q4 25
$-1.29
$-0.68
Q3 25
$-0.32
$0.27
Q2 25
$-0.59
$0.24
Q1 25
$-0.35
$0.19
Q4 24
$-0.33
$0.27
Q3 24
$-0.24
$0.16
Q2 24
$-0.23
$0.14
Q1 24
$-0.35
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
NFBK
NFBK
Cash + ST InvestmentsLiquidity on hand
$95.7M
$164.0M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$690.1M
Total Assets
$502.6M
$5.8B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
NFBK
NFBK
Q4 25
$95.7M
$164.0M
Q3 25
$91.5M
$131.7M
Q2 25
$97.3M
$97.6M
Q1 25
$342.0M
$101.7M
Q4 24
$392.0M
$167.7M
Q3 24
$387.3M
$232.9M
Q2 24
$308.3M
$153.5M
Q1 24
$327.8M
$238.8M
Total Debt
HCAT
HCAT
NFBK
NFBK
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
$666.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
NFBK
NFBK
Q4 25
$245.8M
$690.1M
Q3 25
$331.9M
$719.6M
Q2 25
$347.5M
$710.3M
Q1 25
$376.8M
$711.1M
Q4 24
$365.2M
$704.7M
Q3 24
$355.0M
$699.6M
Q2 24
$357.0M
$693.0M
Q1 24
$357.2M
$698.4M
Total Assets
HCAT
HCAT
NFBK
NFBK
Q4 25
$502.6M
$5.8B
Q3 25
$587.1M
$5.7B
Q2 25
$616.2M
$5.7B
Q1 25
$891.5M
$5.7B
Q4 24
$858.9M
$5.7B
Q3 24
$813.0M
$5.7B
Q2 24
$691.7M
$5.7B
Q1 24
$695.1M
$5.9B
Debt / Equity
HCAT
HCAT
NFBK
NFBK
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
0.95×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
NFBK
NFBK
Operating Cash FlowLast quarter
$9.9M
$53.7M
Free Cash FlowOCF − Capex
$9.6M
$52.5M
FCF MarginFCF / Revenue
12.9%
127.1%
Capex IntensityCapex / Revenue
0.4%
2.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$89.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
NFBK
NFBK
Q4 25
$9.9M
$53.7M
Q3 25
$-464.0K
$13.9M
Q2 25
$-9.0M
$14.1M
Q1 25
$280.0K
$9.4M
Q4 24
$-3.5M
$31.1M
Q3 24
$6.2M
$14.0M
Q2 24
$1.6M
$6.9M
Q1 24
$10.3M
$4.2M
Free Cash Flow
HCAT
HCAT
NFBK
NFBK
Q4 25
$9.6M
$52.5M
Q3 25
$-719.0K
$13.6M
Q2 25
$-9.2M
$13.9M
Q1 25
$-390.0K
$9.2M
Q4 24
$-3.9M
$30.0M
Q3 24
$5.5M
$13.7M
Q2 24
$1.3M
$6.7M
Q1 24
$10.1M
$3.8M
FCF Margin
HCAT
HCAT
NFBK
NFBK
Q4 25
12.9%
127.1%
Q3 25
-0.9%
34.6%
Q2 25
-11.4%
35.7%
Q1 25
-0.5%
26.3%
Q4 24
-4.9%
81.6%
Q3 24
7.2%
43.2%
Q2 24
1.7%
21.1%
Q1 24
13.5%
12.1%
Capex Intensity
HCAT
HCAT
NFBK
NFBK
Q4 25
0.4%
2.8%
Q3 25
0.3%
0.8%
Q2 25
0.3%
0.6%
Q1 25
0.8%
0.7%
Q4 24
0.5%
3.1%
Q3 24
0.9%
0.7%
Q2 24
0.4%
0.8%
Q1 24
0.3%
1.4%
Cash Conversion
HCAT
HCAT
NFBK
NFBK
Q4 25
Q3 25
1.29×
Q2 25
1.48×
Q1 25
1.20×
Q4 24
2.76×
Q3 24
2.14×
Q2 24
1.16×
Q1 24
0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

NFBK
NFBK

Segment breakdown not available.

Related Comparisons